Biomarkers for multiple sclerosis

Internal Medicine

Volumn 53, Issue 5, 2014, Pages 361-365

  Tomioka, Ryo ^a   Matsui, Makoto ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Cerebrospinal fluid; Flow cytometry; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; COMPLEMENT FACTOR H; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 8; L SELECTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NATALIZUMAB; OLIGOCLONAL BAND; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

BLOOD; CEREBROSPINAL FLUID; DISEASE ACTIVITY; HUMAN; MONITORING; MULTIPLE SCLEROSIS; REVIEW; TH1 TH2 BALANCE; DIFFERENTIAL DIAGNOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 84895198226     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.1246     Document Type: Review

References (43)

1. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8: 913-919, 2007.
2. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 39: 6-16, 1996.
3. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69: 292-302, 2011.
4. Nakashima I, Fujihara K, Sato S, Itoyama Y. Ologoclonal IgG bands in Japanese patients with multiple sclerosis. A comparative study between isoelectric focusing with IgG immunofixation and high-resolution agarose gel electrophoresis. J Neuroimmunol 159: 133-136, 2005.
5. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231, 1983.
6. Fortini A, Sanders E, Weisnenker B, et al. Cerebrospinal fluid oligoclonal band in the diagnosis of multiple aclerosis. Am J Clin Pathol 120: 672-675, 2003.
7. Link H, Huang Y-M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 180: 17-28, 2006.
8. Nakashima I, Fujihara K, Itoyama Y. Oligoclonal IgG bands in Japanese multiple sclerosis patients. J Neuroimmunol 101: 205-206, 1999.
9. Mattson DH, Roos RP, Arnason BGW. Oligoclonal IgG in multiple sclerosis and subacute sclerosing panencephalitis brains. J Neuroimmunol 2: 261-276, 1982.
10. Caroscio JT, Kochwa S, Sacks H, Makuku S, Cohen JA, Yahr MD. Quantitative cerebrospinal fluid IgG measurements as a marker of disease activity in multiple sclerosis. Arch Neurol 43: 1129-1131, 1986.
11. Tourtellotte WW, Ma BI. Multiple sclerosis: the blood-brainbarrier and the measurement of de novo central nervous system IgG synthesis. Neurology 28: 76-83, 1978.
12. Disanto G, Moharan JM, Barnett MH, Giovannoni G, Ramagopalan SV. The evidence for a role of B cells in multiple sclerosis. Neurology 78: 823-832, 2012.
13. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112, 2004.
14. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17: 1019-1032, 2010.
15. van Boxel-Dezaire AHH, Hoff SCH, van Oosten BW, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 45: 695-703, 1999.
16. Riekmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-〈 messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 37: 82-88, 1995.
17. Giovannoni G, Kieseier B, Hartung HP. Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 64 (suppl): S31- S36, 1998.
18. Hellings N, Gelin G, Medaer R, et al. Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity. J Neuroimmunol 126: 143-160, 2002.
19. Hartung H-P, Reiners K, Archelos JJ, et al. Circulating adhesion correlation with magnetic resonance imaging. Ann Neurol 38: 186-193, 1995.
20. Trojano M, Avolio C, Simone IL, et al. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd- DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings. Neurology 47: 1535-1541, 1996.
21. Waubant E, Goodkin DE, Gee L, et al. Serum MMP-9 and TIMP- 1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53: 1397-1401, 1999.
22. Ingram G, Hakobyan S, Hirst CL, et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133: 1602-1611, 2010.
23. Ochi H, Wu X-M, Osoegawa M, et al. Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-Iassociated myelopathy/tropical spastic paraparesis and hyper- IgEaemic myelitis. J Neuroimmunol 119: 297-305, 2001.
24. Matsui M, Araya S, Wang HY, Matsushima K, Saida T. Immunomonitoring measures in relapsing-remitting multiple sclerosis. J Neuroimmunol 148: 192-199, 2004.
25. Ochi H, Osoegawa M, Wu X-M, et al. Increased IL-13 but not IL- 5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase. J Neurol Sci 201: 45-51, 2002.
26. Killestein J, Kalkers NF, Meilof JF, Barkhof F, van Lier RAW, Polman CH. TNF〈 production by CD4+ T cells predicts long-term increase in lesion load on MRI in MS. Neurology 57: 1129-1131, 2001.
27. Misu T, Onodera H, Fujihara K, et al. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J Neuroimmunol 114: 207-212, 2001.
28. Wang HY, Matsui M, Araya S, Onai N, Matsushima K, Saida T. Chemokine receptors associated with immunity within and outside the central nervous system in early rerapsing-remitting multiple sclerosis. J Neuroimmunol 133: 184-192, 2002.
29. Fassbender K, Ragoschke A, Rossol S, et al. Increased release of interleukin-12p40 in MS: association with intracerebral inflammation. Neurology 51: 753-758, 1998.
30. Ishizu T, Osoegawa M, Mei F-J, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128: 988-1002, 2005.
31. Miyagishi R, Kikuchi S, Fukazawa T, Tashiro K. Macrophage inflammatory protein-1〈 in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J Neurol Sci 129: 223-227, 1995.
32. Sørensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103: 807-815, 1999.
33. Sørensen TL, Sellebjerg F, Jensen CV, Strieter RM, Ransohoff RM. Chemokines CXCL10 and CCL2. differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol 8: 665-672, 2001.
34. Franciotta D, Martino G, Zardini E, et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 115: 192-198, 2001.
35. Mahad DJ, Howell SJL, Woodroofe MN. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 72: 498-502, 2002.
36. Rinker JR, Trinkaus K, Cross AH. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 67: 1288-1290, 2006.
37. Wang H-Y, Matsui M, Saida T. Immunological disturbances in the central nervous system linked to MRI findings in multiple sclerosis. J Neuroimmunol 125: 149-154, 2002.
38. Matsui M, Araya S, Wang HY, Matsushima K, Saida T. Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis. J Neurol 252: 908-915, 2005.
39. van der Voort LF, Gilli F, Bertolotto A, et al. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Arch Neurol 67: 402-407, 2010.
40. Defer G, Mariotte D, Derache N, et al. CD49d expression as a promising biomarker to monitor natalizumab efficacy. J Neurol Sci 314: 138-142, 2012.
41. Vandenbark AA, Huan J, Agotsch M, et al. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subsets with multiple sclerosis. J Neuroimmunol 215: 125-128, 2009.
42. Namdar A, Nikbin B, Ghabaee M, Bayati A, Izad M. Effect of IFN-β therapy on the frequency and function of CD4+CD25+ regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. J Neuroimmunol 218: 120-124, 2010.
43. Teunissen C, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 4: 32-41, 2005.